BD appoints former Medtronic exec as SVP of investor relations
24 Nov 2021
Executive Change
BD (NYSE:BDX) announced today that it appointed Francesca DeMartino as its SVP of investor relations.
In the role, DeMartino will lead all aspects of communicating the progress of the company’s BD2025 strategy to investors and the financial community regarding the company’s initiatives for driving shareholder value.
DeMartino assumes the role, effective November 29, according to a news release. She has more than 20 years of experience in investor relations, communications and corporate finance. She most recently served as VP of investor relations at Medtronic. She also served as VP for Corporate Communications & VP of Global Communications for Medtronic’s Diabetes Group.
Other roles before Medtronic included stints at Johnson & Johnson, OMRIX Biopharmaceuticals, Macrocure, GCI Group and The Ruth Group, having started her career as a financial analyst in the Health Care Investment Banking Group at Deutcsche Bank.
Franklin Lakes, N.J.–based BD said DeMartino will report to the company’s EVP & CFO, Chris DelOrefice. She takes over for Kristen Stewart, who has been named SVP of Enterprise Strategy & Insights for BD.
“Francesca is an accomplished leader with a long track record of success in investor relations, including extensive experience in the medical technology industry,” DelOrefice said in the release. “She will lead BD’s efforts to highlight key milestones as we deliver on our strategy to drive growth through innovation.”
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.